AC0676

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study

Accutar Biotechnology Announces First Patient Dosed with AC0676 in Phase 1 Study

AETOSWire June 21, 2023

in Patients with Relapsed/Refractory B-cell Malignancies CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on...

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

Accutar Biotechnology Announces FDA Clearance of IND Application for Phase 1 Trial of AC0676 in B-cell Malignancies

AETOSWire February 6, 2023

CRANBURY, N.J. — Accutar Biotechnology, Inc., a biotechnology company focusing on artificial intelligence (AI)-empowered drug discovery, today...